2-(hydroxymethyl)-4-methylpentanoic acid | 76789-47-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-(hydroxymethyl)-4-methylpentanoic acid
• 英文别名: rac-2-(hydroxymethyl)-4-methylpentanoic acid；3-Hydroxy-2-isobutyl-propionsaeure；2-hydroxymethyl-2-methyl-pentanoic acid；4-Methyl-2-(hydroxymethyl)pentanoic acid
• CAS: 76789-47-4
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: ONJOLGIAGJAUMW-UHFFFAOYSA-N

物化性质

• 沸点：
  115-125 °C(Press: 15 Torr)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(hydroxymethyl)-4-methylpentanoic acid 在 氯化亚砜 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 生成 2-(巯基甲基)-4-甲基戊酸
  参考文献：
  名称：

  Cysteine Derivatives as Inhibitors for Carboxypeptidase A:  Synthesis and Structure−Activity Relationships

  摘要：

  A series of cysteine (Cys) derivatives having an alkyl or arylalkyl moiety on the a-amino group of the amino acid have been synthesized as a novel type of inhibitor for carboxypeptidase A. These compounds are readily prepared starting with Cys in an optically active form. The structure-activity relationship study revealed that the inhibitors prepared from D-Cys are much more potent than the corresponding inhibitors obtained from L-CYS, and the most potent inhibitor in the series, (S)-1j with a K-i value of 55 +/- 4 nM, is obtained by introducing a phenethyl moiety on the amino group Of D-CyS. In comparison, the most active inhibitor in the series of 2-substituted 3-mercaptopropanoic acid is found to be 20, in which the phenyl ring is linked to the mercaptocarboxylic acid at the a-position with a methylene unit. A proposal that accounts for the different structural requirement for the maximum activity between the two series of inhibitors is provided.

  DOI：

  10.1021/jm010272s
• 作为产物：
  描述：

  2,2-dimethyl-5-(2-methylpropylidene)-1,3-dioxane-4,6-dione 在 samarium diiodide 、 水 作用下， 以 四氢呋喃 为溶剂， 以87%的产率得到2-(hydroxymethyl)-4-methylpentanoic acid
  参考文献：
  名称：

  通过使用SmI2和H2O选择性还原1,3-二环酸

  摘要：

  SmI 2 / H 2 O可以将环状1,3-二酯还原为3-羟基酸，且不会过度还原。此外，该试剂系统对环状1,3-二酯的选择要高于非环状1,3-二酯和酯的选择。通过单电子还原酯羰基形成的自由基已在分子内加成烯烃中得到利用。缩酮单元和反应温度对环化的非对映选择性具有显着影响。当起始环二酯中存在两个烯烃并导致形成两个具有良好立体控制性的环和四个立体中心时，可能会发生级联级联反应。

  DOI：

  10.1002/chem.201000632

文献信息

• EFTU INHIBITORS OR AMINOTHIAZOLES AND THEIR USES
  申请人：LaMarche Matthew J.

  公开号：US20080221142A1

  公开（公告）日：2008-09-11

  The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.

  本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• [EN] N-MERCAPTOACYL PHENYALANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE N-MERCAPTOACYL PHENYALANINE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLAXO GROUP LTD

  公开号：WO2003104200A1

  公开（公告）日：2003-12-18

  The invention relates to compounds of formula (I); wherein R1 represents C1-6alkyl; R2 represents pyrazole or pyrimidine; or a pharmaceutically acceptable derivative thereof. The invention also relates to pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a ACE and/or NEP inhibitor is indicated.

  这项发明涉及公式(I)的化合物；其中R1代表C1-6烷基；R2代表吡唑或嘧啶；或其药用可接受的衍生物。该发明还涉及含有公式(I)化合物的药物组合物，以及公式(I)化合物在医学中的使用，特别是在改善ACE和/或NEP抑制剂适用的临床病况中的使用。
• N-Substituted mercaptoacyl pripionamides
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04327111A1

  公开（公告）日：1982-04-27

  Mammalian collagenase is inhibited by compounds having the formula ##STR1## or a salt thereof, wherein R.sub.1 is hydrogen, alkanoyl of 2 to 10 carbon atoms, or arylcarbonyl; ##STR2## wherein R.sub.4 is hydrogen, alkyl or aryl; R.sub.3 is alkyl of 3 to 8 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, aryl or arylalkyl; and n is an integer of 1 to 20.

  哺乳动物胶原酶受到具有以下结构式的化合物或其盐的抑制，其中R.sub.1为氢、2到10个碳原子的烷酰基，或芳基羰基；R.sub.4为氢、烷基或芳基；R.sub.3为3到8个碳原子的烷基、3到7个碳原子的环烷基、芳基或芳基烷基；n为1到20的整数。
• Inhibitors of mammalian collagenase
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04235885A1

  公开（公告）日：1980-11-25

  Mammalian collagenase is inhibited by compounds having the formula ##STR1## and salts thereof, wherein R.sub.1 is hydrogen or alkanoyl of 2 to 10 carbon atoms; R.sub.2 is hydroxy, amino, or ##STR2## R.sub.3 is hydrogen, alkyl of 1 to 4 carbon atoms, ##STR3## R.sub.4 is hydroxy, amino, arginine, leucine, glutamine, alanine or glycine; and m is 0 or an integer of 1 to 9.

  哺乳动物胶原酶被具有以下结构式##STR1##及其盐所抑制，其中R.sub.1是氢或2到10个碳原子的烷酰基；R.sub.2是羟基、氨基或##STR2##；R.sub.3是氢、1到4个碳原子的烷基、##STR3##；R.sub.4是羟基、氨基、精氨酸、亮氨酸、谷氨酰胺、丙氨酸或甘氨酸；m为0或1到9的整数。